- Home
- EYPT vs SFL Comparison
EYPT vs SFL Comparison
Compare EYPT & SFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | SFL |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Marine Transportation |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2005 | 2004 |
Fundamental Metrics
Financial Performance| Metric | EYPT | SFL |
|---|---|---|
| Price | $13.97 | $10.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $31.80 | $12.00 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 7.05% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,115.57 | $13.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.41 | $6.73 |
| 52 Week High | $19.11 | $12.94 |
Technical Indicators
Market Signals| Indicator | EYPT | SFL |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 41.82 |
| Support Level | $12.01 | $9.83 |
| Resistance Level | $14.52 | $11.30 |
| Average True Range (ATR) | 1.05 | 0.34 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 51.38 | 35.02 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.